Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study
-
- Franco Dammacco
- Sections of Internal Medicine and Clinical Oncology,
-
- Felicia Anna Tucci
- Sections of Internal Medicine and Clinical Oncology,
-
- Gianfranco Lauletta
- Sections of Internal Medicine and Clinical Oncology,
-
- Pietro Gatti
- Sections of Internal Medicine and Clinical Oncology,
-
- Valli De Re
- Clinical and Experimental Pharmacology, Department of Molecular Oncology and Translational Research, Centro di Riferimento Oncologico Aviano, Pordenone, Italy
-
- Vincenza Conteduca
- Sections of Internal Medicine and Clinical Oncology,
-
- Silvia Sansonno
- Clinical and Experimental Pharmacology, Department of Molecular Oncology and Translational Research, Centro di Riferimento Oncologico Aviano, Pordenone, Italy
-
- Sabino Russi
- Sections of Internal Medicine and Clinical Oncology,
-
- Maria Addolorata Mariggiò
- General Pathology and Experimental Oncology, and
-
- Maria Chironna
- Hygiene, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari; and
-
- Domenico Sansonno
- Sections of Internal Medicine and Clinical Oncology,
書誌事項
- 公開日
- 2010-07-22
- DOI
-
- 10.1182/blood-2009-10-245878
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>This study illustrates the use and efficacy of a combination of pegylated interferon-α (Peg-IFN-α) and ribavirin (RBV), with or without rituximab (RTX), in hepatitis C virus (HCV)–related mixed cryoglobulinemia (MC). Twenty-two patients with HCV-related MC received Peg-IFN-α (2a: 180 μg or 2b: 1.5 μg/kg) weekly plus RBV (1000 or 1200 mg) daily for 48 weeks, and RTX (375 mg/m2) once a week for 1 month followed by two 5-monthly infusions (termed PIRR). Fifteen additional patients received Peg-IFN-α/RBV with the same modalities as the PIRR schedule. Complete response was achieved in 54.5% (12/22) and in 33.3% (5/15) of patients who received PIRR and Peg-IFN-α/RBV, respectively (P < .05). Clearance of HCV RNA and conversion of B-cell populations from oligoclonal to polyclonal in liver, bone marrow, and peripheral blood was maintained for up to 3 years in 10 of 12 (83.3%) and in 2 of 5 (40%) patients receiving PIRR and Peg-IFN-α/RBV, respectively (P < .01). Cryoproteins in 22.7% (5/22) of patients with PIRR and in 33.3% (5/15) with Peg-IFN-α/RBV persisted despite sustained HCV RNA clearance. No response occurred in remaining 5 patients of both groups. PIRR therapy is well tolerated and more effective than Peg-IFN-α/RBV combination in HCV-related MC. Its effect may last for more than 3 years.</jats:p>
収録刊行物
-
- Blood
-
Blood 116 (3), 343-353, 2010-07-22
American Society of Hematology